Podcasts about btcs

Kyle Reidhead is the Founder of Impact3 and Co-Owner of The Milk Road.In this episode, we provide a comprehensive guide on ETH treasury companies, publicly traded firms focused on acquiring and staking ETH for their balance sheets, while tapping into DeFi to earn yield. We explore how these firms raise capital to buy more ETH, how staking/DeFi differentiates them from BTC treasury companies, why metrics like mNAV, share count, and ETH purchase-to-issuance ratio matter, and how this new Wall Street phenomenon is driving an outsized bid to buy a shrinking supply of ETH.------

In this episode, we sit down with Charles Allen, CEO of BTCS, one of the first publicly traded crypto infrastructure companies, to reveal how ETH treasury strategies are reshaping markets. Charles explains how BTCS ditched Bitcoin, went all-in on Ethereum, and built a flywheel of staking, block building, and DeFi leverage that could crush traditional ETH ETFs. If ETH hits $10K, these treasury companies will be the ones leading the charge, and Charles has been doing it for years before Wall Street even noticed.~~~~~

A daily update on what's happening in the Rocket Pool community on Discord, Twitter, Reddit, and the DAO forum. #RocketPool #rpl #Ethereum #eth #crypto #cryptocurrency #staking #news Podcast RSS: https://anchor.fm/s/cd29a3d8/podcast/rss Anchor.fm: https://anchor.fm/rocket-fuel Spotify: https://open.spotify.com/show/0Mvta9d2MsKq2u62w8RSoo Apple Podcasts: https://podcasts.apple.com/us/podcast/rocket-fuel/id1655014529 0:00 - Welcome Rocket Pool news0:55 - Security council tests https://discord.com/channels/405159462932971535/405163979141545995/13974374389511619502:55 - Smart Node adds BTCS relay https://twitter.com/Rocket_Pool/status/1948295021712535774 4:40 - Votes end vote.rocketpool.net 6:51 - rETH on Pendle on Base https://x.com/pendle_fi/status/1948352530569933218 8:47 - Phiz's talks Rocket Pool decentralization https://x.com/superphiz/status/1947630024355364884? 11:23 - Sleety teases new Saturn explainer website https://discord.com/channels/405159462932971535/405163713063288832/1397963921268281495 Staking news 12:18 - Big unstaking validators numbershttps://www.validatorqueue.com/ https://x.com/crypto_condom/status/1947750202401796535 https://x.com/tiza4thepeople/status/1947724231631937733 https://x.com/robdogeth/status/1948033585404878957 20:57 - NodeSet to support Commit Boost https://discord.com/channels/968587363536220252/1153574664174579842/1397105007832334407 https://twisty-wednesday-4be.notion.site/Commit-Boost-Reducing-Risks-and-Returning-Autonomy-Over-the-Block-Back-to-Ethereum-s-Validators-0f309f76058e447388381c60550ce67b 21:51 - Client release https://github.com/NethermindEth/nethermind/releases/tag/1.32.3 Ethereum news 22:18 - Post Pectra blobs https://x.com/hildobby/status/1947667969900703976? 26:35 - Bitmine thriving! https://x.com/fundstrat/status/1948351129399546308?s https://en.cryptonomist.ch/2025/07/22/ark-invest-bets-on-ethereum-and-revolutionizes-the-market/ https://x.com/JourneyMacro/status/1947510717416149133 https://x.com/fundstrat/status/1948114342680879306?s 29:25 - SBET's weekly buy details https://x.com/SharpLinkGaming/status/1947649643955032171 32:18 - Seriously, those ETF flows! https://x.com/NateGeraci/status/1948203466016342116 https://x.com/nategeraci/status/1948363118880412118? https://farside.co.uk/eth/ 36:56 - Base is 10x faster! https://x.com/jessepollak/status/1948411158979080248 38:20 - Linea token coming https://x.com/ethereumjoseph/status/1947291741226242555 In other news 39:43 - Banks start crypto relationships https://www.theblock.co/amp/post/363836/pnc-deal-coinbase-crypto-bank-customers40:59 - Coinwatch Track https://x.com/coinwatchdotco/status/1947326598245441696 42:52 - Roman Storm case https://x.com/theragetech/status/1947342132559184382 https://x.com/cryptonator1337/status/1947378245957259653? https://vxtwitter.com/L0laL33tz/status/1948005498252378553

De beweging waarbij bedrijven beursgenoteerde aandelen gebruiken om grote hoeveelheden crypto aan te kopen, is overgeslagen van Bitcoin naar Ethereum. Het fenomeen begon enkele jaren geleden met MicroStrategy, maar inmiddels duiken ook zogeheten Ethereum Treasury Companies op. Deze bedrijven gebruiken hun beursnotering om Ethereum aan te kopen en op de balans te zetten. De belofte is simpel: meer Ethereum voor je euro, via een omweg op de beurs. Dat roept vragen op over hun strategie, geloofwaardigheid en toekomst. De eerste noemenswaardige onderneming die deze stap zette was Sharplink Gaming, kortweg SBET. Een kleine partij, zonder duidelijke omzetstromen, maar wél met een uitgesproken plan: alleen Ether op de balans. De koersbeweging van het aandeel laat een patroon zien dat vaker voorkomt bij dit soort bedrijven: eerst een forse stijging, gevolgd door een correctie, en daarna een periode van herstel. SBET wil uiteindelijk voor maximaal vijf miljard dollar aan Ethereum kopen. Of dat realistisch is, hangt mede af van hun vermogen om geld op te halen via de aandelenmarkt. SBET is niet de enige partij die deze richting inslaat. Kort na hen kondigde Bit Mine Immersion Technologies aan zich om te vormen tot een Ethereum Treasury Company. Oorspronkelijk was dit een miner, actief op het Bitcoin-netwerk. Ook Bit Digital en BTCS zijn bezig hun strategie aan te passen. Het meest in het oog springend is echter DYNX, een bedrijf dat inmiddels al 400.000 Ether heeft aangekocht — ter waarde van ongeveer anderhalf miljard dollar. De namen achter deze onderneming zijn nog niet publiek bekend, maar in de markt wordt gespeculeerd over overnames en samenwerkingen. Er lijkt zich langzaam een nieuwe hype te vormen, vergelijkbaar met die rond Bitcoin-aandelen zoals MicroStrategy. Toch presteren veel van die bedrijven op de beurs niet bijzonder goed, mede door hun afhankelijkheid van het sentiment op de cryptomarkt. De vraag is of Ethereum Treasury Companies hetzelfde lot te wachten staat, of dat ze op tijd kunnen bouwen aan een overtuigend narratief. Ondertussen kijkt de bredere DLT-community met argusogen toe. Tools en platforms ontstaan om beleggers te helpen navigeren in dit nieuwe speelveld. Is dit het begin van een nieuwe fase in de cryptomarkt, of juist het einde van een zeepbel? Gasten Jasper Oelers Raoul Esseboom Links De Lange Termijn Strategicethreserve.xyz Host Daniël Mol Redactie Daniël MolSee omnystudio.com/listener for privacy information.

Charles Allen, CEO of BTCS, joined me to discuss why BTCS chose Ethereum as its treasury asset—and why he believes it's a better option than Bitcoin.Topics: - BTCS history of innovation in the crypto space - Using Ethereum as a treasury asset - Why Ethereum is better than other crypto assets for a treasury strategy - Staking and DeFi - Will crypto treasury companies survive the bear market? - Crypto legislation and market outlook Show Sponsor -

A daily update on what's happening in the Rocket Pool community on Discord, Twitter, Reddit, and the DAO forum. #RocketPool #rpl #Ethereum #eth #crypto #cryptocurrency #staking #news Podcast RSS: https://anchor.fm/s/cd29a3d8/podcast/rss Anchor.fm: https://anchor.fm/rocket-fuel Spotify: https://open.spotify.com/show/0Mvta9d2MsKq2u62w8RSoo Apple Podcasts: https://podcasts.apple.com/us/podcast/rocket-fuel/id1655014529 0:00 - Welcome 1:05 - Price action teaser Rocket Pool news2:58 - Devnet-3 for Saturn released https://discord.com/channels/405159462932971535/405163979141545995/1394916250634686576 5:05 - New smart node release https://discord.com/channels/405159462932971535/918351974406172723/1394843977525629070 https://discord.com/channels/405159462932971535/1395030218267426846 7:15 - BTCS talking to the Rocket Pool community https://discord.com/channels/405159462932971535/405163713063288832/1394794929603084429 https://discord.com/channels/405159462932971535/405163713063288832/1394798841244549150 https://x.com/philosowrapter/status/1945216447493390696 https://discordapp.com/channels/405159462932971535/1376176509101932554/1395114912430161930 11:11 - rETH loan migration campaign on Liquity https://x.com/LiquityProtocol/status/1945165625065660880 12:43 - Users banned on discord https://discord.com/channels/405159462932971535/998627604686979214/1394874175751196783 Staking news 14:12 - NodeSet exit some validators https://discord.com/channels/968587363536220252/1153574664174579842/1395216176392437811 Ethereum news 15:15 - SBET biggest ETH holder - nope! https://x.com/sharplinkgaming/status/1945094437173940389 https://x.com/fabdarice/status/1945124035853213847 https://x.com/fabdarice/status/1945941608756896030 https://x.com/BitMNR/status/1945857172237393982 https://x.com/fundstrat/status/1945914730469609961 https://x.com/JoshwaaaDixon/status/1945851138407792793 https://x.com/hanni_abu/status/1945937648159219715 https://x.com/fabdarice/status/1945852636877729799 https://x.com/cointelegraph/status/1946034913410433468?s=46 24:17 - Gargantuan ETH ETF days https://farside.co.uk/eth/ https://x.com/NateGeraci/status/1946027987620581877 https://discord.com/channels/405159462932971535/405163713063288832/1395591742220144650 28:46 - Blackrock ETH staking ETF https://x.com/ethereanvibin/status/1945890788304449726 31:46 - ETH shortage on markets https://www.cryptopolitan.com/wintermute-no-eth-left-sale-otc-desk/ https://x.com/drjasper_eth/status/1945980788761047268 35:33 - 45m gas! https://gaslimit.pics/ 36:31 - EIPs in Glamsterdam explained https://x.com/notnotstorm/status/1945138261434777825 39:27 - Vitalik talks L1s becoming Ethereum L2s https://x.com/vitalikbuterin/status/1945053518655619341? In other news 41:11 - Crypto laws all pass house https://x.com/Cointelegraph/status/1945987096302301290 45:49 - Coinbase wallet https://x.com/samuellhuber/status/1945510645539254571? https://x.com/base/status/1945624674656030985 48:19 - Retirement accounts to allow crypto? https://x.com/watcherguru/status/1945952623674237200 50:01 - Most bullish day ever for ETH? https://x.com/sassal0x/status/1945983948770926675 https://x.com/sassal0x/status/1946035234543407545 https://x.com/iamDCinvestor/status/1946018325676593368

Ether is up 50% against Bitcoin since April, breaking key resistance levels. Corporations now hold over $5 billion in ETH, which is one of the key reasons behind the Ether boom. ETH still lags behind in 2025 returns, leaving room for upside.~This Episode is Sponsored By Coinbase~ Buy $50 & Get $50 for getting started on Coinbase➜ https://bit.ly/CBARRON00:00 Intro00:14 Sponsor: Coinbase00:35 Regulation Fail01:45 CNBC: Voting schedule03:15 CNBC: Crypto bounce04:50 Retail + Google trends05:40 Hedgefunds06:10 Trump x Fed07:10 El-Erian: Fed should cut but they won't08:50 CNBC: Bitcoin Top signal?09:30 Fear & Greed10:10 Ethereum's next identity11:15 $SBET #111:57 $BTCS sleeper13:25 Best $ETH beta play15:00 BlackHole AVAX catalyst15:35 BONK flying16:00 Outro#Ethereum #crypto #Bitcoin~Ethereum Takes Over!

Which stocks have you found using AI through a prompt? Today I have 2 for you that have early characteristics of $AMZN $NFLX $NVDA and other high fliers. Here are the links to all the sales: ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠SAVE ON TRENDSPIDER - SUMMER SALE FOR $9 - GET THE ANNUAL SUBSCRIPTION TO GET MY 4 HOUR ALGORITHM ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠

A daily update on what's happening in the Rocket Pool community on Discord, Twitter, Reddit, and the DAO forum. #RocketPool #rpl #Ethereum #eth #crypto #cryptocurrency #staking #news Podcast RSS: https://anchor.fm/s/cd29a3d8/podcast/rss Anchor.fm: https://anchor.fm/rocket-fuel Spotify: https://open.spotify.com/show/0Mvta9d2MsKq2u62w8RSoo Apple Podcasts: https://podcasts.apple.com/us/podcast/rocket-fuel/id1655014529 0:00 - Welcome Rocket Pool news0:47 - Team funding update https://discord.com/channels/405159462932971535/1271919130525831279/1390407291181727907 6:44 - Votes hit quorum vote.rocketpool.net https://discord.com/channels/405159462932971535/894377758489210930/1394362968116039770 9:53 - Gitcoin removed from oDAO https://discord.com/channels/405159462932971535/894377758489210930/1394161792430899220 10:48 - RP effectiveness thread https://discord.com/channels/405159462932971535/1029031967947231242/1393194696695611464 https://rocketpool.steely-test.org/ 12:22 - IMC Budget https://dao.rocketpool.net/t/imc-period-37-report-period-38-budget/3682 Staking news 14:03 - NodeSet rewards coming soon https://discord.com/channels/405159462932971535/1070004025610739883/1393019119363686490 Ethereum news 14:52 - SBET buys from EF https://x.com/SharpLinkGaming/status/1943642068859199786 https://x.com/ethereumfndn/status/1943642682825523320? https://x.com/maxxTFSA/status/1943698447015567742 https://x.com/maxxTFSA/status/1943755322369139002 https://x.com/cointelegraph/status/1944011448918614215? https://intel.arkm.com/explorer/entity/sharplink-gaming 20:00 - ETF flows at record levels https://x.com/NateGeraci/status/1943491299409101039 21:17 - New ETH strategies comes online https://x.com/fabdarice/status/1943681720609554741? https://x.com/cloutedmind/status/1943861524579463670? https://x.com/fabdarice/status/1943706157161615505 https://coingeek.com/bit-digital-shifts-from-btc-mining-to-eth-staking/ https://x.com/hanni_abu/status/1943713465362747886? 28:54 - The ETH Report for Q2 https://x.com/ryansadams/status/1944824244602315239 33:05 - BTCS fix their block building & update https://x.com/philosowrapter/status/1943500263458750874 https://x.com/drjasper_eth/status/1943516638852026853 https://x.com/NasdaqBTCS/status/1943279194395250901 https://x.com/nasdaqbtcs/status/1944706335347478986 35:50 - GMX exploiter returns funds! https://x.com/olimpiocrypto/status/1943634991763648884 https://x.com/itskkoma/status/1943643244824580309 In other news 37:12 - Crypto Week in US government https://www.cryptoinamerica.com/p/crypto-week-commences-lawmakers-and https://x.com/NateGeraci/status/1944523045273551189

A daily update on what's happening in the Rocket Pool community on Discord, Twitter, Reddit, and the DAO forum. #RocketPool #rpl #Ethereum #eth #crypto #cryptocurrency #staking #news Podcast RSS: https://anchor.fm/s/cd29a3d8/podcast/rss Anchor.fm: https://anchor.fm/rocket-fuel Spotify: https://open.spotify.com/show/0Mvta9d2MsKq2u62w8RSoo Apple Podcasts: https://podcasts.apple.com/us/podcast/rocket-fuel/id1655014529 0:00 - Welcome 0:46 - Bullish crypto price https://www.binance.com/en/trade/BTC_USDT?theme=dark&type=spot https://www.binance.com/en/trade/ETH_USDT?theme=dark&type=spot https://www.binance.com/en/trade/RPL_USDT?theme=dark&type=spot https://discord.com/channels/405159462932971535/405503016234385409/1392614114609729556 Rocket Pool news3:48 - RPIP 72 vote live https://vote.rocketpool.net/#/proposal/0x836e0fcb86b41ff45b075910eeeae53c14af80d3b2a91f89e13904407f871d8e 5:46 - IMC elections live https://vote.rocketpool.net/#/proposal/0xe97b77711428fccba2740871edd4c1ed1e26721ff3a15b08370813c4cf5c877d 8:42 - rETH in Liquity v2 https://discord.com/channels/405159462932971535/405163713063288832/1392508879253798962 https://liquity.app/ 10:13 - rETH yield strategy https://x.com/factor_fi/status/1943235373418844234? 12:22 - 2 new minipools dissolved https://discord.com/channels/405159462932971535/894377118828486666/1392783916091441162 Staking news 13:29 - Client updates https://github.com/sigp/lighthouse/releases/tag/v7.1.0 https://github.com/status-im/nimbus-eth2/releases/tag/v25.7.0 14:24 - Tailscale changing IP address rules https://discord.com/channels/405159462932971535/1070004025610739883/1392521408474648576 Ethereum news 15:27 - hugely bullish ETH reports https://x.com/ryansadams/status/1942742550982373816 https://x.com/fundstrat/status/1943314579792040001 https://institutional.fidelity.com/app/literature/view?itemCode=9919383&renditionType=PDF https://x.com/MariaShen/status/1942658782439395815 24:47 - BTCS up their dollar raise target https://x.com/charles_btcs/status/1942901597488447922? https://x.com/nasdaqbtcs/status/1942563971791204695 https://www.youtube.com/watch?v=-JunBkcr_so 27:37 - Financial games with treasury companies https://x.com/laurashin/status/1942967401450201345 31:01 - EF ecosystem engagement change https://x.com/ethereumfndn/status/1943321131144089661 https://x.com/james_gaps/status/1943302929965842710 33:33 - GMX hacked https://x.com/Mudit__Gupta/status/1942949671699206159 34:11 - Growthepie update https://x.com/growthepie_eth/status/1943293328746819817?s In other news 36:47 - US Treasury changing broker rules https://x.com/watcherguru/status/1943322047980900589?

Shares of SharpLink Gaming (SBET) surged after the online gaming firm said it snapped up another 7,689 ether (ETH) for its corporate treasury. Other Ethereum treasury stocks are also exploding.~This episode is sponsored by Tangem~Tangem ➜ https://bit.ly/TangemPBNUse Code: "PBN" for Additional Discounts!00:00 Intro00:14 Sponsor: Tangem00:45 Sharplink closes market01:00 NASDAQ01:33 They bought more ETH too02:00 Joe Lubin hints at buying more Ethereum than expected02:36 Bit Digital turns into an ETH Maxi04:00 $BTCS: $100M in ETH05:12 MEGA-MERGER possible05:40 Joseph Lubin mentions BTCS on cnbc 07:05 Bitcoin Maxi's Shorting ETH?07:14 Staking skyrocketing07:50 Still early07:20 Microsoft08:50 ETH approaching all-time high transactions09:30 Fusaka upgrade incoming10:00 Eric Trump wall - Feb 3rd10:50 Vlad September11:13 OutroEthereum #Crypto #bitcoin~ETH Takes Over Wallstreet!

BTCS Inc. has announced its strategic intent to raise $100 million in 2025 to acquire Ethereum and support the growth of its ETH-first infrastructure model. The strategy is designed to increase ETH per share, drive scalable revenue, and minimize shareholder dilution.~This episode is sponsored by Tangem~Tangem ➜ https://bit.ly/TangemPBNUse Code: "PBN" for Additional Discounts!Guest: Charles Allen, CEO and Chairman of the Board at BTCSBTCS Website ➜ https://bit.ly/BTCSethereum00:00 intro00:15 Sponsor: Tangem00:55 Four Years Later01:20 What is $BTCS?01:49 Ethereum Treasury Strategy02:50 Bitcoin vs ETH Business Model04:10 Tom Lee on Circle IPO05:20 BTCS name change?06:19 Record Revenue07:35 Sharplink vs BTCS08:34 Aave Borrowing09:14 Buying $100 Million More ETH!10:16 Tom Lee: ETH Company Mergers Incoming?11:00 BTCS + Tom Lee Merger?12:48 Bitcoin exiting to Ethereum14:56 Schwab Excited About Tokenized Stocks16:05 Ethereum Hype Incoming17:29 Tom Lee: Ethereum "WallStreet Put"19:25 Technical Expertise Needed20:26 Polymarket Dominates Politics21:41 Gaming Will Surpass Countries21:56 Michael Saylor Buying ETH?23:33 outro#Crypto #Ethereum #bitcoin ~$100mil Ethereum Mega-Strategy!

In recent years, an increasing number of companies has embraced Bitcoin as part of their corporate treasury strategy. Matthew Sigel, VanEck's head of digital assets research, warned that some companies might be on the brink of “capital erosion.” In simple terms, capital erosion occurs when a company's value (or shareholders' equity) diminishes despite the company's holdings in Bitcoin.~This Episode is Sponsored By Coinbase~ Buy $50 & Get $50 for getting started on Coinbase➜ https://bit.ly/CBARRON00:00 Intro00:13 Sponsor: Coinbase00:44 Bitcoin Treasury List01:30 Cathie: Microstrategy Premium will fall02:30 BTC Maxis vs ETH03:05 Another Bitcoin Company Moves to ETH03:30 BTCS: First Bitcoin Miner moves to ETH05:27 Microsoft waiting on staking ETF's06:02 Enterprise Ethereum Alliance06:52 Google CEO: Younger demographics vs Bitcoin07:20 Tokenized Gold more trusted than Bitcoin soon?07:57 Jim Cramer cries over Apple stock09:56 Apple Q1 data10:42 Creator Economy Coming to ETH11:33 Outro#Crypto #Ethereum #Bitcoin~Bitcoin Treasury Hype Dead or Early?

Toni Wahrstätter outlined the trade-offs of EIP-7928. The EF introduces the Trillion Dollar Security initiative. BTCS secures up to $58 million to buy ETH. And EigenDA V2 goes live on testnet. Read more: https://ethdaily.io/703 Disclaimer: Content is for informational purposes only, not endorsement or investment advice. The accuracy of information is not guaranteed.

In episode 95, we take a journey back to 1998 and revisit Before These Crowded Streets, the haunting, ambitious, and sonically rich album that redefined Dave Matthews Band. We break down the album track by track, exploring its musicianship, lyrics, and collaborations that made it a standout in DMB's catalog.  Join us as we unpack the lasting impact of BTCS—an album that continues to captivate fans over 25 years later. 

47e6GvjL4in5Zy5vVHMb9PQtGXQAcFvWSCQn2fuwDYZoZRk3oFjefr51WBNDGG9EjF1YDavg7pwGDFSAVWC5K42CBcLLv5U OR DONATE HERE: https://www.monerotalk.live/donate LINKS: https://x.com/AaronRDay TIMESTAMPS (00:00:00) Monerotopia Introduction. (00:15:27) Monerotopia Guest Segment w/ Aaron Day. (01:14:35) Monerotopia Price Report Segment w/ Bawdyanarchist. (02:01:08) Monerotopia News Segment w/ Tony. (02:01:35) ETH credit score (02:03:45) CBP ramps up ASIC miner crackdown with seizures. (02:04:45) Jack Maller and Dorsey talking about privacy coins. (02:06:12) El Salvador refusing BTC (02:07:23) Shopinbit report (02:08:00) US dollar back on a gold standard? (02:08:28) Monero upcoming updates (02:12:30) BTCs to ETFs (02:14:05) ROOMBA Vacuum exploited (02:17:05) Reuters paid by the feds (02:18:12) No Biometrics on Iphone. (02:20:53) JD Vance at the Munich conference. (02:24:31) Digital communism. (02:27:47) Monerotopia Viewers on Stage Segment. (03:25:15) Monerotopia Finalization. NEWS SEGMENT LINKS: JD Vance at the Munich conference: https://x.com/cryptotweetie/status/1890780627303076006?s=46&t=mVZ0A2C1bwwnAvgawJjlw PlanB transferred his BTC: https://x.com/vikrantnyc/status/1890779528848364014?s=46&t=mVZ0A2C1bwwnAvgawJjlw Shopinbit report: https://x.com/janowitz/status/1889611772245520531?s=46&t=mVZ0A2C1bwwnAvgawJjlw Iphone biometrics: https://x.com/creon/status/1888663088087658920?s=46&t=mVZ0A2C1bwwnAvgawJjlw Digital communism: https://x.com/7sees/status/1888610862916575587?s=46&t=mVZ0A2C1bwwnAvgawJjlw El Salvador refusing BTC: https://x.com/twopeopleinpara/status/1888659689983857044?s=46&t=mVZ0A2C1bwwnAvgawJjlw ETH credit score: https://x.com/cryptonator1337/status/1889067397380010423?s=46&t=mVZ0A2C1bwwnAvgawJjlw US dollar back on a gold standard?: https://x.com/adamemedia/status/1889562025816150145?s=46&t=mVZ0A2C1bwwnAvgawJjlw Jack Maller and Dorsey talking about privacy coins: https://x.com/alekceikozlov/status/1889899550892343466?s=46&t=mVZ0A2C1bwwnAvgawJjlw Reuters paid by the feds: https://x.com/elonmusk/status/1890182649974817070?s=46&t=mVZ0A2C1bwwnAvgawJjlw ROOMBA Vacuum exploited: https://x.com/xx17965797n/status/1890372808493924366?s=46&t=mVZ0A2C1bwwnAvgawJjlw ASICS seized: https://blockspace.media/insight/cbp-ramps-up-asic-miner-crackdown-with-seizures-new-import-holds/ Monero upcoming updates: https://www.reddit.com/r/Monero/s/53dkAfxVhk SPONSORS: PRICE REPORT: https://exolix.com/ GUEST SEGMENT: https://cakewallet.com & https://monero.com NEWS SEGMENT: https://www.wizardswap.io Don't forget to SUBSCRIBE! The more subscribers, the more we can help Monero grow! XMRtopia TELEGRAM: https://t.me/monerotopia XMRtopia MATRIX: https://matrix.to/#/%23monerotopia%3Amonero.social ODYSEE: https://bit.ly/3bMaFtE WEBSITE: monerotopia.com CONTACT: monerotopia@protonmail.com MASTADON: @Monerotopia@mastodon.social MONERO.TOWN https://monero.town/u/monerotopia Get Social with us: X: https://twitter.com/monerotopia INSTAGRAM: https://www.instagram.com/monerotopia DOUGLAS: https://twitter.com/douglastuman SUNITA: https://twitter.com/sunchakr TUX: https://twitter.com/tuxpizza

A daily update on what's happening in the Rocket Pool community on Discord, Twitter, Reddit, and the DAO forum. #RocketPool #rpl #Ethereum #eth #crypto #cryptocurrency #staking #news Podcast RSS: https://anchor.fm/s/cd29a3d8/podcast/rss Anchor.fm: https://anchor.fm/rocket-fuel Spotify: https://open.spotify.com/show/0Mvta9d2MsKq2u62w8RSoo Apple Podcasts: https://podcasts.apple.com/us/podcast/rocket-fuel/id1655014529 0:00 - Welcome Rocket Pool news 0:38 - Obol airdrop for RPers https://claim.obol.org/ https://x.com/Obol_Collective/status/1881719066685218818 BTCS running RP validators https://x.com/charles_btcs/status/1879535119834222974?s=46 https://www.btcs.com/wp-content/uploads/2025/01/Scaled-Validator-Implementation-PR-January-15-2025-vF2.pdf Exit arb in action https://discordapp.com/channels/405159462932971535/405163713063288832/1331019773097807872 Jasper talks to Trump team https://discord.com/channels/405159462932971535/998627604686979214/1330543231070375997 https://x.com/worldlibertyfi/status/1881457386671464804?s=46 https://etherscan.io/tx/0xf5f38c2394a3d1121b87e444a0c8f604d12359ea33a715433172f0fe63b1c52b NSSO stop selling rETH https://discord.com/channels/405159462932971535/405163713063288832/1330606728496156753 https://discord.com/channels/405159462932971535/405503016234385409/1331331113565556876 More contango incentives https://discord.com/channels/405159462932971535/405163713063288832/1329825934055833620 Liquify v2 date https://x.com/liquityprotocol/status/1881366913479328080?s=46 Boosted HAI rewards https://x.com/letsgethai/status/1879912357499207882 Rescue Node change in ownership https://x.com/Rescue_Node/status/1879952774970110114 AlphaGrowth's lost deals https://discord.com/channels/405159462932971535/1300824467076808776/1330992398180028556 DAO reports https://dao.rocketpool.net/t/pdao-2024-12-19-2025-01-16-treasury-report/3481 https://dao.rocketpool.net/t/imc-period-30-31-reports-period-31-32-budgets/3485 STAR application deadline passes https://dao.rocketpool.net/t/looking-for-overseer-for-the-star-initiative-reth-incubator/3475 Staking news Gas limit increase https://x.com/sassal0x/status/1879672562663514288 https://x.com/trent_vanepps/status/1879896778809786543? CSM going permissionless https://discord.com/channels/405159462932971535/405163713063288832/1329779113887535134 NodeSet rewards claiming soon https://discord.com/channels/968587363536220252/1153574664174579842/1329834713699057776 Ethereum news EF leadership discussion https://x.com/dannyryan/status/1879705279761178690? https://x.com/vitalikbuterin/status/1880635379771904423?s=46 https://x.com/VitalikButerin/status/1880637064158626267 https://x.com/vitalikbuterin/status/1881347052279349300?s=46 https://x.com/vitalikbuterin/status/1881298926650929415?s=46 https://x.com/vitalikbuterin/status/1881300872984166689?s=46 https://x.com/vitalikbuterin/status/1881350360381685816?s=46 https://x.com/dannyryan/status/1881742086703096313?s=46 https://x.com/vitalikbuterin/status/1881680518934384676?s=46 https://x.com/ethereumjoseph/status/1881721024057598309? Pectra timeline https://x.com/terencechain/status/1879892324353991052? https://x.com/nixorokish/status/1879893269028737138? https://x.com/terencechain/status/1879892324353991052 https://x.com/christine_dkim/status/1879919371684127176 In other news SEC Crypto Taskforce https://x.com/news_of_alpha/status/1881760567116829087? https://x.com/nategeraci/status/1881763205716025513?

Ein neuer Präsident, neue Kryptowährungen und neue Versprechungen. Bei Interesse und/oder für mehr Informationen zu meinem 2-Tägigen Finanzseminar (Frühjahr 2025), schreibe mir einfach eine kurze E-Mail an:  krapp@abatus-beratung.com Viel Spaß beim Hören,Dein Matthias Krapp(Transkript dieser Folge weiter unten) NEU!!! Hier kannst Du Dich kostenlos für meinen Minikurs registrieren und reinschauen. Es lohnt sich: https://portal.abatus-beratung.com/geldanlage-kurs/   

Conviértete en miembro de este canal para disfrutar de videos solo disponibles para miembros: https://www.youtube.com/channel/UC4DBbWZ3S16HxxgCLI5saAA/join *********************************************************************** #bitcoin #btc #etf Esto te puede interesar si quieres cambiar tu vida: - Enlace para suscribirte a la Newsletter de Crypto Mercados y Pymes: https://www.cryptomercadosypymes.com/ - Enlace para suscribirte a la Newsletter de PERITAJES TIC en la que vas a encontrar casos judiciales reales en los que un peritaje digital hace ganar el caso. Cuando lo leas te darás cuenta de que la realidad supera a la ficción: https://peritajestic.com/ - Escríbeme a este mail si la suscripción a la newsletter o la Masterclass te da problemas: cryptomercadosypymes@gmail.com *********************************************************************** Os dejo varios enlaces de afiliación: Un primer enlace a la web de la billetera fría Ledger: https://shop.ledger.com/?r=96c89dbd786b Este enlace de afiliados de Tradingview: https://es.tradingview.com/?aff_id=29244 Este enlace a servicios de dominios web y alojamiento de Webempresa: https://clientes.webempresa.com/europa/gestion/aff.php?aff=2121 *********************************************************************** Y este enlace de Amazon a varios libros muy recomendables: 1. "La filosofía de Bitcoin" de Álvaro D. María: https://amzn.to/3KiB5EE 2. ·"Imbatible. La fórmula para alcanzar la libertad financiera" de Tony Robbins: https://amzn.to/3yA003K 3. "Ten peor coche que tu vecino" de Luis Pita: https://amzn.to/3R2nQeR 4. "El sutil arte de que (casi todo) te importe una mi@rda" de Mark Manson : https://amzn.to/45aE4HZ 5. "La psicología del dinero. Cómo piensan los ricos". Morgan Housel: https://amzn.to/3WYj7Pi 6. "La medusa inmortal. Todo lo que hay que saber para vivir más años" de Nicklas Brendborg: https://amzn.to/4aDktSB 7. "El futuro de la humanidad". Michiu Kaku: https://amzn.to/3ysIPB2 *********************************************************************** Disclaimer: este video y su contenido son solo para fines informativos y no constituyen una oferta de venta o intercambio, una solicitud de compra o recomendación de ningún valor, criptomoneda o producto relacionado, ni constituye una oferta para proporcionar inversión asesoramiento u otros servicios relacionados por parte de Crypto Mercados y Pymes. Crypto Mercados y Pymes puede tener una inversión financiera con las criptomonedas discutidas en este video. Al preparar este video, NO se han tenido en cuenta las necesidades financieras o de inversión individuales del espectador ni se ofrece ningún consejo financiero o de inversión. Todas las opiniones expresadas en este video se prepararon en función de la información disponible en el momento en que se escribieron y/o publicaron dichas opiniones. Información modificada o adicional podría hacer que tales opiniones cambien. *********************************************************************** Crypto Mercados y Pymes, el mejor canal online sobre mercados financieros y criptomonedas: #bitcoin #cryptocurrency #news #btc #ethereum #eth #cryptocurrency #litecoin #altcoin #altcoins #forex #money #best #trading #bitcoinmining #invest #trader #cryptocurrencies #top #investing #entrepreneur #business #success #investment #finance #motivation #coinbase #stocks #wallstreet #investor #wealth #bullish #bearish #cryptolive #altcoindaily *********************************************************************** cryptocurrency, crypto, altcoin, altcoin daily, news, best investment, top altcoins, las mejores altcoins, ripple, la mejor inversion en cripto, best crypto investment, ethereum, xrp, crash, bottom, suelo, crash, price, precio, predicción, prediction, podcast, interview, entrevista,finanzas,finance, stock, investment, inversión, too late, demasiado tarde, bitcoin, cryptocurrency news, noticias de criptomonedas, bitcoin news, noticias de bitcoin, cryptocurrency news media online, noticias de criptomonedas online, defi, finanzas descentralizadas, ¿debería comprar bitcoin?, ¿debería comprar Ethereum?, bitcoin una buena inversión, la mejor inversión cripto, ethereum una buena inversión, ethereum a good investment, best crypto investments, predicción 2024, 2024 prediction, nfts, los mejores ntfs, best nfts, ¿debería comprar cardano?, should I buy cardano?, coin bureau, binance, coinbase, coffeezilla,

Bienvenido a Entorno Blockchain Podcast

Conviértete en miembro de este canal para disfrutar de videos solo disponibles para miembros: https://www.youtube.com/channel/UC4DBbWZ3S16HxxgCLI5saAA/join *********************************************************************** #bitcoin #btc #etf Esto te puede interesar si quieres cambiar tu vida: - Enlace a la Masterclass CARTERA METAMASK: https://www.cryptomercadosypymes.com/landing-metamask/ - Enlace para suscribirte a la Newsletter de Crypto Mercados y Pymes: https://www.cryptomercadosypymes.com/ - Enlace para suscribirte a la Newsletter de PERITAJES TIC en la que vas a encontrar casos judiciales reales en los que un peritaje digital hace ganar el caso. Cuando lo leas te darás cuenta de que la realidad supera a la ficción: https://peritajestic.com/ - Escríbeme a este mail si la suscripción a la newsletter o la Masterclass te da problemas: cryptomercadosypymes@gmail.com *********************************************************************** Os dejo varios enlaces de afiliación: Un primer enlace a la web de la billetera fría Ledger: https://shop.ledger.com/?r=96c89dbd786b Este enlace de afiliados de Tradingview: https://es.tradingview.com/?aff_id=29244 Este enlace a servicios de dominios web y alojamiento de Webempresa: https://clientes.webempresa.com/europa/gestion/aff.php?aff=2121 *********************************************************************** Y este enlace de Amazon a varios libros muy recomendables: 1. "La filosofía de Bitcoin" de Álvaro D. María: https://amzn.to/3KiB5EE 2. ·"Imbatible. La fórmula para alcanzar la libertad financiera" de Tony Robbins: https://amzn.to/3yA003K 3. "Ten peor coche que tu vecino" de Luis Pita: https://amzn.to/3R2nQeR 4. "El sutil arte de que (casi todo) te importe una mi@rda" de Mark Manson : https://amzn.to/45aE4HZ 5. "La psicología del dinero. Cómo piensan los ricos". Morgan Housel: https://amzn.to/3WYj7Pi 6. "La medusa inmortal. Todo lo que hay que saber para vivir más años" de Nicklas Brendborg: https://amzn.to/4aDktSB 7. "El futuro de la humanidad". Michiu Kaku: https://amzn.to/3ysIPB2 *********************************************************************** Disclaimer: este video y su contenido son solo para fines informativos y no constituyen una oferta de venta o intercambio, una solicitud de compra o recomendación de ningún valor, criptomoneda o producto relacionado, ni constituye una oferta para proporcionar inversión asesoramiento u otros servicios relacionados por parte de Crypto Mercados y Pymes. Crypto Mercados y Pymes puede tener una inversión financiera con las criptomonedas discutidas en este video. Al preparar este video, NO se han tenido en cuenta las necesidades financieras o de inversión individuales del espectador ni se ofrece ningún consejo financiero o de inversión. Todas las opiniones expresadas en este video se prepararon en función de la información disponible en el momento en que se escribieron y/o publicaron dichas opiniones. Información modificada o adicional podría hacer que tales opiniones cambien. *********************************************************************** Crypto Mercados y Pymes, el mejor canal online sobre mercados financieros y criptomonedas: #bitcoin #cryptocurrency #news #btc #ethereum #eth #cryptocurrency #litecoin #altcoin #altcoins #forex #money #best #trading #bitcoinmining #invest #trader #cryptocurrencies #top #investing #entrepreneur #business #success #investment #finance #motivation #coinbase #stocks #wallstreet #investor #wealth #bullish #bearish #cryptolive #altcoindaily *********************************************************************** cryptocurrency, crypto, altcoin, altcoin daily, news, best investment, top altcoins, las mejores altcoins, ripple, la mejor inversion en cripto, best crypto investment, ethereum, xrp, crash, bottom, suelo, crash, price, precio, predicción, prediction, podcast, interview, entrevista,finanzas,finance, stock, investment, inversión, too late, demasiado tarde, bitcoin, cryptocurrency news, noticias de criptomonedas, bitcoin news, noticias de bitcoin, cryptocurrency news media online, noticias de criptomonedas online, defi, finanzas descentralizadas, ¿debería comprar bitcoin?, ¿debería comprar Ethereum?, bitcoin una buena inversión, la mejor inversión cripto, ethereum una buena inversión, ethereum a good investment, best crypto investments, predicción 2024, 2024 prediction, nfts, los mejores ntfs, best nfts, ¿debería comprar cardano?, should I buy cardano?, coin bureau, binance, coinbase, coffeezilla,

Agradece a este podcast tantas horas de entretenimiento y disfruta de episodios exclusivos como éste. ¡Apóyale en iVoox! Conviértete en miembro de este canal para disfrutar de videos solo disponibles para miembros: https://www.youtube.com/channel/UC4DBbWZ3S16HxxgCLI5saAA/join *********************************************************************** #bitcoin #btc #etf Esto te puede interesar si quieres cambiar tu vida: - Enlace a la Masterclass CARTERA LAST CALL: https://www.cryptomercadosypymes.com/landing-cartera-last-call/ - Enlace para suscribirte a la Newsletter de Crypto Mercados y Pymes: https://www.cryptomercadosypymes.com/ - Enlace para suscribirte a la Newsletter de PERITAJES TIC en la que vas a encontrar casos judiciales reales en los que un peritaje digital hace ganar el caso. Cuando lo leas te darás cuenta de que la realidad supera a la ficción: https://peritajestic.com/ - Escríbeme a este mail si la suscripción a la newsletter o la Masterclass te da problemas: cryptomercadosypymes@gmail.com *********************************************************************** Os dejo varios enlaces de afiliación: Un primer enlace a la web de la billetera fría Ledger: https://shop.ledger.com/?r=96c89dbd786b Este enlace de afiliados de Tradingview: https://es.tradingview.com/?aff_id=29244 Este enlace a servicios de dominios web y alojamiento de Webempresa: https://clientes.webempresa.com/europa/gestion/aff.php?aff=2121 *********************************************************************** Y este enlace de Amazon a varios libros muy recomendables: 1. "La filosofía de Bitcoin" de Álvaro D. María: https://amzn.to/3KiB5EE 2. ·"Imbatible. La fórmula para alcanzar la libertad financiera" de Tony Robbins: https://amzn.to/3yA003K 3. "Ten peor coche que tu vecino" de Luis Pita: https://amzn.to/3R2nQeR 4. "El sutil arte de que (casi todo) te importe una mi@rda" de Mark Manson : https://amzn.to/45aE4HZ 5. "La psicología del dinero. Cómo piensan los ricos". Morgan Housel: https://amzn.to/3WYj7Pi 6. "La medusa inmortal. Todo lo que hay que saber para vivir más años" de Nicklas Brendborg: https://amzn.to/4aDktSB 7. "El futuro de la humanidad". Michiu Kaku: https://amzn.to/3ysIPB2 *********************************************************************** Disclaimer: este video y su contenido son solo para fines informativos y no constituyen una oferta de venta o intercambio, una solicitud de compra o recomendación de ningún valor, criptomoneda o producto relacionado, ni constituye una oferta para proporcionar inversión asesoramiento u otros servicios relacionados por parte de Crypto Mercados y Pymes. Crypto Mercados y Pymes puede tener una inversión financiera con las criptomonedas discutidas en este video. Al preparar este video, NO se han tenido en cuenta las necesidades financieras o de inversión individuales del espectador ni se ofrece ningún consejo financiero o de inversión. Todas las opiniones expresadas en este video se prepararon en función de la información disponible en el momento en que se escribieron y/o publicaron dichas opiniones. Información modificada o adicional podría hacer que tales opiniones cambien. *********************************************************************** Crypto Mercados y Pymes, el mejor canal online sobre mercados financieros y criptomonedas: #bitcoin #cryptocurrency #news #btc #ethereum #eth #cryptocurrency #litecoin #altcoin #altcoins #forex #money #best #trading #bitcoinmining #invest #trader #cryptocurrencies #top #investing #entrepreneur #business #success #investment #finance #motivation #coinbase #stocks #wallstreet #investor #wealth #bullish #bearish #cryptolive #altcoindaily *********************************************************************** cryptocurrency, crypto, altcoin, altcoin daily, news, best investment, top altcoins, las mejores altcoins, ripple, la mejor inversion en cripto, best crypto investment, ethereum, xrp, crash, bottom, suelo, crash, price, precio, predicción, prediction, podcast, interview, entrevista,finanzas,finance, stock, investment, inversión, too late, demasiado tarde, bitcoin, cryptocurrency news, noticias de criptomonedas, bitcoin news, noticias de bitcoin, cryptocurrency news media online, noticias de criptomonedas online, defi, finanzas descentralizadas, ¿debería comprar bitcoin?, ¿debería comprar Ethereum?, bitcoin una buena inversión, la mejor inversión cripto, ethereum una buena inversión, ethereum a good investment, best crypto investments, predicción 2024, 2024 prediction, nfts, los mejores ntfs, best nfts, ¿debería comprar cardano?, should I buy cardano?, coin bureau, binance, coinbase, coffeezilla,Escucha este episodio completo y accede a todo el contenido exclusivo de Crypto Mercados y Pymes. Descubre antes que nadie los nuevos episodios, y participa en la comunidad exclusiva de oyentes en https://go.ivoox.com/sq/1336498

ANNETTE TUDOR BTCS DIRECTOR OF SCHOOLS JULY 23See omnystudio.com/listener for privacy information.

00:00 - No episódio de hoje... 01:54 - EUA com problemas, ainda comprar dólar e ativos? 08:54 - Alteração do mandato no BC por Lula: risco? 09:37 - Lula influencia dólar? Setores beneficiados com câmbio alto? 12:56 - Bacen acertou ao não intervir no dólar? 13:25 - Confiança dos investidores nas declarações de Lula e Haddad? 15:37 - Risco de política de empréstimos baixos após saída do RCN? 16:29 - Blocos econômicos são viáveis ou utopia capitalista? 18:19 - Reserva de 350 bi pode cobrir dívida crescente de 200 bi/ano? 19:03 - Chance de taxação de Fiis e Fiagro? 19:50 - Setor resistente à inflação? 21:43 - Governo gasta mais, Bacen aumenta passivo? 23:44 - BTCs em CEX são arriscados em crash mundial? 24:41 - Juros antigos ainda afetam inflação? 27:21 - Trump e impostos: agravamento fiscal dos EUA? 29:47 - Êxodo de milionários no Reino Unido: soluções para crescimento? 31:33 - Próxima temporada do Nas Fronteiras do Dinheiro? O "Ulrich Responde" é uma série de vídeos em que respondo perguntas enviadas por membros do canal e seguidores onde abordo diversos tópicos relacionados à economia, finanças e investimentos Nesse formato de vídeo falamos sobre política econômica, inflação, taxas de juros, até investimentos em criptomoedas e ações, oferecendo uma análise aprofundada e bem fundamentada em cada episódio, trazendo informação para quem busca entender melhor a economia e tomar decisões financeiras mais informadas

Featuring perspectives from Ms Blanca Ledezma, Dr Stacey Stein, Ms Amanda K Wagner and Dr Mark Yarchoan, including the following topics: Introduction (0:00) Adjuvant Therapy for Early-Stage Hepatocellular Carcinoma (HCC) (9:40) Role of Immunotherapy in Intermediate-Stage HCC (17:02) First-Line Therapy for Advanced HCC (19:56) Immunotherapy in the Management of Advanced Biliary Tract Cancers (BTCs) (44:29) Biomarker Testing Recommendations and the Use of FGFR Inhibitors for Advanced Cholangiocarcinoma (58:02) Potential Role of HER2-Targeted Therapy for BTCs (1:17:16) CME information and select publications  

It was an absolute honor having DMB & music industry legend Steve Lillywhite join us live from "The Lillipad" for Convos on the Corner! This has truly been years in the making and because he has been a part of many interviews in his career, we wanted to make this one as fresh and unique as possible.  In Part 1, we dive into how Steve got his start in music, what he's up to these days, and touch on some of the other bands he has worked with including The Rolling Stones, Phish, Peter Gabriel, Talking Heads, and of course U2 who he recently joined in Vegas to help prepare for their residency at The Sphere. We also discussed his incredible work with DMB on UTTAD, Crash, BTCS and the Lillywhite Sessions. Oh, and we actually had Steve listen to infamous MacHead and give us his reaction to hearing it again after all of these years, what it needed to have in order to have made the album, and the story behind its "lyrics". We hope you enjoy this enlightening convo with Steve - and be sure to come back next week for Part 2 where we discuss his works with Phish, the current band he'd want to produce, and an extended discussion about his potential final DMB record, Away From the World. 

By Selva Ozelli. Author of Sustainably Investing in Digital Assets Globally The veil on the identity of Satoshi Nakamoto, the author of Bitcoin's White Paper that proposed the blockchain-based decentralized crypto currency, still has not been lifted. This "'identity issue,' namely whether Dr. Craig Wright is the pseudonymous 'Satoshi Nakamoto,' i.e., the person who created Bitcoin in 2009" or not according to high court judge John Mellor is still being litigated in the UK with the support of Bitcoin Legal Defense Fund set up by Block CEO Jack Dorsey. Is Dr. Craig Wright Satoshi Nakamoto? "The Bitcoin Legal Defense Fund is a nonprofit entity that aims to minimize legal headaches that discourage software developers from actively developing Bitcoin and related projects such as the Lightning Network, Bitcoin privacy protocols, and the like," explained Jack. Unfortunately, the self-proclaimed inventor of Bitcoin, Dr. Craig Wright is only one of many to claim to be Satoshi Nakamoto according to an article "The Faketoshi" authored by Arthur van Pelt. Adding layers to Satoshi's identity mystery is a Binance wallet sending approximately $1.2 million worth of BTCs to Satoshi's genesis wallet on January 5, 2024, two days after BTC's 15th Birthday. The mist around Dr. Craig's 'identity issue' is expected to lift "By 4 pm on January 18, 2024, [when] Dr Wright and COPA shall exchange and shall serve on the Developer Defendants expert reports on (a) forensic document analysis in respect of the Additional Documents,- [95 documents dating back to 2007] - stored on the Samsung Drive, and the BDO Drive; and (b) LaTeX software," Mellor added. Once the identity of Satoshi is known, if this person is a US person with an estimated BTC wealth of $41B the US taxpayer is expected to file Form 8300 with the IRS by January 20, 2024 for the $1.2M in BTC received since effective January 1 2024, any crypto transaction over $10,000 must be electronically (if they are required to file certain other information returns electronically) reported. Noncompliance with Form 8300 subject's taxpayer to civil and criminal penalties. Bad Actors Out of the Way While the "real" author of the Bitcoin White Paper continues to being debated in the UK court system, the Digital Asset industry went through a cleansing of bad actors in the US during 2023. The world's largest Digital Asset Exchange Binance and its CEO pleaded guilty to federal charges and agreed to pay over $4B to resolve the Justice Department's investigation into violations related to the Bank Secrecy Act, failure to register as a money transmitting business, and the International Emergency Economic Powers Act (IEEPA). See: https://crypto.news/binance-founder-and-ceo-plead-guilty-to-federal-charges-opinion/ Binance, Coinbase, Terraform Labs and others also faced action by the SEC for operating unregistered securities exchanges which are ongoing. "In 2023, the U.S. experienced significant regulatory shifts, particularly in response to the FTX collapse which was followed by five crypto-friendly bank failures. The Biden administration's 'regulation by enforcement' strategy shaped the federal landscape, spearheaded by Gary Gensler and the SEC. Amidst this, states like Colorado stood out as beacons for the crypto industry, accounting for 33% of all U.S. crypto businesses. This success is primarily attributed to forward-thinking measures such as Colorado's 'Digital Token Act' and key initiatives like ETH Denver, all nurtured under Governor Jared Polis' vision" explained Sergiu Hamza, CEO of Coincub which prepared Reports on US MSB and global VASPs . North American investors, money managers and even CBOE Digital president John Palmer is confident that a new wave of institutional and pension fund investment will follow spot Bitcoin ETF approvals. Already several spot BTC exchange-traded fund (ETF) applicants Vaneck, Valkyrie, Grayscale Investments Fidelity BlackRock, and Bitwise filed to register their funds as secu...

While the band has been on a much deserved break, so have we, but as some of the DMB family hit the road again, so did we. Nolan was lucky enough to catch Tim Reynolds and Joe Lawlor in Raleigh, NC last week as TR3 kicked off their fall tour in style. We recap this special night and highlight how incredible it is to be up close and personal with these true musical virtuosos. We also finally give our opinions surrounding the good and bad surrounding the BTCS 25th anniversary re-release and related merch. It's good to be back and we hope you all enjoy!

In today's EMERGENCY EPISODE; Jeanette, Trisha, Matt, and Shawn discuss the announcement of the long awaited 25th anniversary BTCS vinyl.

As all of you are well aware, Reliability Matters is all about reliability, specifically reliability of circuit assemblies. One challenge that seems to be persistent within our space is design for manufacturability, or DfM. If you're a contract manufacturer, no doubt you've had the experience of being asked to build a product that seems unbuildable. One example that rings true was the introduction of bottom terminated components or BTCs. BTC's are marvelous components. Because all the lead terminations are below the part, they permit highly dense component placement and highly miniaturized assemblies. They also presented a number of unique challenges in reflow, in many cases voiding, cleaning, and inspection. Like many other industries, we are not immune to the introduction of new technologies that may lack implementation knowledge. We then spend the next several years at technical conferences and symposiums learning us how to implement these new technologies. There are many acronyms in our industry that begin with Df…  Design for testability, mechanical assembly, serviceability, reliability, and so many more. So many in fact, that there is a placeholder acronym for all of the various design fours refer to as DFx. Perhaps the holy grail of DFx is DfM (design for manufacturability) as it encompasses so many aspects of assembly. Today Andrew Williams helps us understand what exactly DFM is. He is engineering manager for electronics manufacturing at PRIDE Industries. He has more than 30 years of experience in manufacturing and design and holds an SMT Process Engineer certification from SMTA and an IPC Certified Electronics Program Manager. He is a guest lecturer at UC Davis and Cal State University Sacramento for Supply Chain Management, Operations, and TQM courses, and speaks frequently on DfM, DfS, and other DfX topics.

This week, our Special Guest, Brian Foster takes the lead, exploring the significance of the recent ETF applications, Coinbase's role in this space, and explains the surveillance sharing aspect. He dives into why now is an opportune time for ETFs and discusses their relation to other ways of accessing bitcoin and crypto, including Coinbase's own retail business.Josh provides a market update, covering the biggest movers and the latest trends in NFT floors. He also discusses BTCs positive dynamics, the Binance.US discount, DCG-related news, and developments in the Polygon and Arbitrum ecosystems.David covers important upcoming economic indicators such as CPI, PPI, and earnings reports from notable institutions like JPM and Citi. He also runs through the Cancun upgrade roadmap and the recent progress of L2 scaling solutions.Greg analyzes flows and volatility, sharing insights on BTC and ETH basis. He also discusses the recent trends in the Bored Ape NFT market.Sid addresses recent multichain hacks, providing analysis and insights into their impact on the crypto landscape and looks forward to EthCC in Paris next week.Please, don't forget to like and subscribe so others can benefit from the team's great content!HostBen Floyd, Head of Execution ServicesSpecial GuestBrian Foster, Director Americas Institutional SalesPresentersJoshua Pak, CES SalestraderDavid Duong, Head of Institutional ResearchGreg Sutton, Senior CES SalestraderSid Shekar, Engineering ManagerLink to Research and Insights Hubhttps://www.coinbase.com/institutional/research-insights

Featuring perspectives from Dr Anthony El-Khoueiry, Dr Robin K (Katie) Kelley and Prof Arndt Vogel, includingthe following topics: Hepatocellular Carcinoma (HCC) Introduction (0:00) Adjuvant therapy for HCC (1:47) First-line systemic therapy for advanced/metastatic HCC (10:36) Management of HCC in the second-line setting and beyond (18:27) Biliary Tract Cancers (BTCs) First-line systemic therapy for metastatic BTCs (26:41) Management of metastatic cholangiocarcinoma with FGFR fusions/rearrangements (35:16) Management of metastatic cholangiocarcinoma with IDH1 mutations  (43:54) Management of metastatic HER2-positive BTC (48:47) CME information and select publications

Featuring perspectives from Drs Eric Lee, Neil Morganstein and Swati Vishwanathan, including the following topics: •      Gastroesophageal Cancers — Zev Wainberg, MD, MSc  o   Introduction (0:00) o   Systemic therapy considerations for HER2-negative localized gastroesophageal cancers (4:33) o   First-line systemic therapy for metastatic esophageal or gastric cancer (10:05) o   Zolbetuximab/chemotherapy as first-line treatment for HER2-negative, locally advanced unresectable or metastatic gastric and gastroesophageal junction cancers (16:19) o   Repeat tissue biopsy versus circulating tumor DNA testing for HER2-positive GI cancers after disease progression on first-line therapy (20:59) o   Trastuzumab deruxtecan as second-line therapy for HER2-positive gastric cancer; management of CNS disease (25:05) •      Hepatobiliary Cancers — Lipika Goyal, MD, MPhil  o   Tissue biopsy for suspected hepatocellular carcinoma (HCC) (29:59) o   Atezolizumab/bevacizumab versus durvalumab/tremelimumab as first-line therapy for HCC; disease etiology and response to treatment (33:34) o   Liver-directed therapy in the era of effective novel systemic regimens (40:50) o   First-line, single-agent immunotherapy for HCC (44:33) o   Sequencing tyrosine kinase inhibitors for patients with HCC with and without contraindications to immunotherapy (47:46) o   Survival benefit with durvalumab/gemcitabine/cisplatin for advanced biliary tract cancers (BTCs) in the TOPAZ-1 trial — A new standard? (51:25) o   Spectrum of targetable genetic alterations in BTCs; novel FGFR2 inhibitors for cholangiocarcinoma (54:28) CME information and select publications

Go online to PeerView.com/FKB860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. New science continues to support a diverse management model for advanced biliary tract cancers (BTCs), including immune-based and targeted platforms, culminating to the first meaningful advancements in frontline therapy for advanced/metastatic BTC in over a decade. Collectively these clinical trends have expanded the use of individualized management strategies, leading to enhanced clinical outcomes for patients with advanced BTC. In this activity, based on a recent live symposium, expert panelists provide data and practical guidance on the current status of care in BTC and new developments related to the use of novel and emerging immunotherapies and targeted options (eg, PD-1 and PD-L1 inhibitors, FGFR, IDH, TRK, and HER2-directed agents). Case presentations explore next-generation care for today's patients with BTC using personalized upfront and sequential treatment management models. Don't miss this chance to get personal with advanced BTC! Upon completion of this activity, participants should be better able to: Summarize the latest clinical evidence supporting the use of immunotherapy and targeted platforms for patients with advanced BTCs; Develop personalized management plans for patients with advanced BTCs based on up-to-date clinical evidence on novel immunotherapeutic and targeted approaches, expert recommendations, comorbidities, and other factors at baseline; and Manage unique safety considerations associated with the use of novel targeted and immunotherapy options for BTCs

Go online to PeerView.com/FKB860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. New science continues to support a diverse management model for advanced biliary tract cancers (BTCs), including immune-based and targeted platforms, culminating to the first meaningful advancements in frontline therapy for advanced/metastatic BTC in over a decade. Collectively these clinical trends have expanded the use of individualized management strategies, leading to enhanced clinical outcomes for patients with advanced BTC. In this activity, based on a recent live symposium, expert panelists provide data and practical guidance on the current status of care in BTC and new developments related to the use of novel and emerging immunotherapies and targeted options (eg, PD-1 and PD-L1 inhibitors, FGFR, IDH, TRK, and HER2-directed agents). Case presentations explore next-generation care for today's patients with BTC using personalized upfront and sequential treatment management models. Don't miss this chance to get personal with advanced BTC! Upon completion of this activity, participants should be better able to: Summarize the latest clinical evidence supporting the use of immunotherapy and targeted platforms for patients with advanced BTCs; Develop personalized management plans for patients with advanced BTCs based on up-to-date clinical evidence on novel immunotherapeutic and targeted approaches, expert recommendations, comorbidities, and other factors at baseline; and Manage unique safety considerations associated with the use of novel targeted and immunotherapy options for BTCs

Go online to PeerView.com/FKB860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. New science continues to support a diverse management model for advanced biliary tract cancers (BTCs), including immune-based and targeted platforms, culminating to the first meaningful advancements in frontline therapy for advanced/metastatic BTC in over a decade. Collectively these clinical trends have expanded the use of individualized management strategies, leading to enhanced clinical outcomes for patients with advanced BTC. In this activity, based on a recent live symposium, expert panelists provide data and practical guidance on the current status of care in BTC and new developments related to the use of novel and emerging immunotherapies and targeted options (eg, PD-1 and PD-L1 inhibitors, FGFR, IDH, TRK, and HER2-directed agents). Case presentations explore next-generation care for today's patients with BTC using personalized upfront and sequential treatment management models. Don't miss this chance to get personal with advanced BTC! Upon completion of this activity, participants should be better able to: Summarize the latest clinical evidence supporting the use of immunotherapy and targeted platforms for patients with advanced BTCs; Develop personalized management plans for patients with advanced BTCs based on up-to-date clinical evidence on novel immunotherapeutic and targeted approaches, expert recommendations, comorbidities, and other factors at baseline; and Manage unique safety considerations associated with the use of novel targeted and immunotherapy options for BTCs

Go online to PeerView.com/FKB860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. New science continues to support a diverse management model for advanced biliary tract cancers (BTCs), including immune-based and targeted platforms, culminating to the first meaningful advancements in frontline therapy for advanced/metastatic BTC in over a decade. Collectively these clinical trends have expanded the use of individualized management strategies, leading to enhanced clinical outcomes for patients with advanced BTC. In this activity, based on a recent live symposium, expert panelists provide data and practical guidance on the current status of care in BTC and new developments related to the use of novel and emerging immunotherapies and targeted options (eg, PD-1 and PD-L1 inhibitors, FGFR, IDH, TRK, and HER2-directed agents). Case presentations explore next-generation care for today's patients with BTC using personalized upfront and sequential treatment management models. Don't miss this chance to get personal with advanced BTC! Upon completion of this activity, participants should be better able to: Summarize the latest clinical evidence supporting the use of immunotherapy and targeted platforms for patients with advanced BTCs; Develop personalized management plans for patients with advanced BTCs based on up-to-date clinical evidence on novel immunotherapeutic and targeted approaches, expert recommendations, comorbidities, and other factors at baseline; and Manage unique safety considerations associated with the use of novel targeted and immunotherapy options for BTCs

Go online to PeerView.com/FKB860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. New science continues to support a diverse management model for advanced biliary tract cancers (BTCs), including immune-based and targeted platforms, culminating to the first meaningful advancements in frontline therapy for advanced/metastatic BTC in over a decade. Collectively these clinical trends have expanded the use of individualized management strategies, leading to enhanced clinical outcomes for patients with advanced BTC. In this activity, based on a recent live symposium, expert panelists provide data and practical guidance on the current status of care in BTC and new developments related to the use of novel and emerging immunotherapies and targeted options (eg, PD-1 and PD-L1 inhibitors, FGFR, IDH, TRK, and HER2-directed agents). Case presentations explore next-generation care for today's patients with BTC using personalized upfront and sequential treatment management models. Don't miss this chance to get personal with advanced BTC! Upon completion of this activity, participants should be better able to: Summarize the latest clinical evidence supporting the use of immunotherapy and targeted platforms for patients with advanced BTCs; Develop personalized management plans for patients with advanced BTCs based on up-to-date clinical evidence on novel immunotherapeutic and targeted approaches, expert recommendations, comorbidities, and other factors at baseline; and Manage unique safety considerations associated with the use of novel targeted and immunotherapy options for BTCs

On todays show I do live TA on Bitcoin and the rest of the crypto currency market. As Bitcoin has shown a bit of volatility today I will let you know what I think BTCs next move will be. We will be taking a look at the key levels you need to be watching for your next trades and where I will be expecting some strong resistance. At the end of the stream we will be spinning the wheel of pain and pleasure where you will have the chance to win some free crypto! Join Bitget NOW for an exchange that puts users first! ➡️ https://partner.bitget.com/bg/FrankieCandles Join my PREMIUM Discord! ➡️ https://mee6.gg/m/frankiecandlespremium Join My FREE Discord! ➡️ https://discord.gg/FrankieCandles Do you like the custom indicators? Get them here! ➡️ https://bitlabacademy.com/ref/FrankieCandles/

O desenvolvedor Luke Dashjr, colaborador há muitos anos do Bitcoin Core, anunciou no dia 1 de janeiro de 2023 que sua chave PGP teria sido comprometida e, junto com ela, centenas de BTCs teriam sido roubados. Esse anúncio, sem detalhes, gerou algumas repercussões interessantes que achei importantes comentar a respeito. Será que é impossível fazer segurança de Bitcoin se até mesmo uma grande figura experiente, considerada especialista, pode cometer erros? Será que esse desenvolvedor é um risco para o Bitcoin em si por ser uma figura importante dentro da implementação de referência do protocolo, a Bitcoin Core? Ocorrência com o desenvolvedor Luke Dashjr https://twitter.com/LukeDashjr/status/1609613748364509184 Tweets sobre o ocorrido: https://twitter.com/bitdov/status/1609727946947952640 https://twitter.com/bitdov/status/1609983860338573312 https://twitter.com/bitdov/status/1609730870369456131 Vídeo recente sobre porque sacar o Bitcoin da corretora https://youtu.be/7fsWG0VIXAc Vídeo Peter Safesrc https://www.youtube.com/watch?v=2uLlUIahr1E Playlist Hardwallet Bitcoin Faça você mesmo https://www.youtube.com/playlist?list=PLgcVYwONyxmjTL7yTCLcpUqiTyyLKm83s Playlist Criação segura de seed BIP39 https://www.youtube.com/playlist?list=PLgcVYwONyxmiz-CzJmqQHKyJm8-t6Tp8p Gravado no bloco 770145 ________________ APOIE O CANAL https://bitcoinheiros.com/apoie/ ⚡ln@pay.bitcoinheiros.com Loja dos Bitcoinheiros https://loja.bitcoinheiros.com/ SIGA OS BITCOINHEIROS: Site: https://www.bitcoinheiros.com Youtube: https://www.youtube.com/bitcoinheiros Twitter: https://www.twitter.com/bitcoinheiros Allan - https://www.twitter.com/allanraicher Dov - https://twitter.com/bitdov Becas - https://twitter.com/bksbk6 Ivan - https://twitter.com/bitofsilence Instagram: https://www.instagram.com/bitcoinheiros Facebook: https://www.fb.com/bitcoinheiros Podcast: https://anchor.fm/bitcoinheiros COMO GUARDAR SEUS BITCOINS? Bitcoinheiros recomendam o uso de carteiras Multisig com Hardware Wallets de diferentes fabricantes ou próprias. Para ver as carteiras de hardware que recomendamos, acesse https://www.bitcoinheiros.com/carteiras Veja os descontos e clique nos links de afiliados para ajudar o canal Por exemplo, para a COLDCARD - https://store.coinkite.com/promo/bitcoinheiros Com o código "bitcoinheiros" você ganha 5% de desconto na ColdCard Playlist "Canivete Suíço Bitcoinheiro" https://www.youtube.com/playlist?list=PLgcVYwONyxmg-KH5bwzMU4sdyMbVMPqwb Playlist "Carteiras Multisig de Bitcoin" https://www.youtube.com/playlist?list=PLgcVYwONyxmi74PiIUSnGie --- Send in a voice message: https://anchor.fm/bitcoinheiros/message

JCO PO author Dr. Mark Yarchoan, MD, of Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, shares research on the four distinct subsets of biliary tract cancers (BTCs) and their varying immune responses and mutations. Dr. Naqash and Dr. Yarchoan discuss the article's study of intrahepatic cholangiocarcinoma [IHC], extrahepatic cholangiocarcinoma, and gallbladder cancer. Click here to read the article! Dr. Naqash: Welcome to ASCO's JCO Precision Oncology Conversations where we bring you the highlights and overview of precision oncology. Episodes will feature engaging conversations with authors of clinically relevant and highly impactful and significant JCO PO articles. These articles can be accessed at ascopubs.org/journals/po. Hi, I am Dr. Rafeh Naqash, Assistant Professor of Medicine at Oklahoma University Stephenson Cancer Center, where I focus on Phase I clinical trials and lung cancer. You're listening to JCO Precision Oncology Conversations podcast. Today, I will be talking with Dr. Mark Yarchoan about his recent paper, Clinical, Genomic, and Transcriptomic Data Profiling of Biliary Tract Cancer Reveals Subtype-Specific Immune Signatures. Dr. Yarchoan is an Associate Professor of Medicine in the GI Medical Oncology branch at the Johns Hopkins, Sydney Kimmel Comprehensive Cancer Center. Full disclosure for our guests will be linked in the show notes and can be found on the article's publication page. Dr. Yarchoan, thank you so much for joining us today. Dr. Yarchoan: Thank you for having me. Dr. Naqash: For the sake of our listeners, Mark, could you tell us about your professional background and your research interests? Dr. Yarchoan: Sure. I'm a medical oncologist by training focused on hepatobiliary malignancies at the Johns Hopkins Hospital, a co-director of Liver Multidisciplinary Clinic, and I'm interested in novel immunotherapeutic approaches to treating liver cancers. Dr. Naqash: That is definitely an unmet need, which we're going to talk about more as we discuss your paper. Again, for the sake of our listeners, before we take a deeper dive into the published paper, could you provide us a one-minute overview of the main findings from your manuscript that was published in JCO Precision Oncology? Dr. Yarchoan: Absolutely. So, we looked at the molecular subtypes of cholangiocarcinoma. So, there are essentially two common forms of liver cancer. There's hepatocellular carcinoma and biliary tract cancers, also sometimes called cholangiocarcinomas. Cholangiocarcinomas are the rarer of the two types of liver cancer and we know that cholangiocarcinoma's not really one cancer, it's a number of different cancers that all anatomically start within the bile ducts of the liver. And what we did working with a number of different collaborators and then also, with Tempus, which is a major molecular profiling company, is we looked at the landscape of mutations that occur in cholangiocarcinoma, and then tried to correlate these mutations with features of the tumor immune microenvironment using RNA data from the same tumors. Dr. Naqash: Thank you so much. So, again, being a thoracic oncologist myself, we have a lot of excitement associated with immune checkpoint alone or immune checkpoint in combination with chemotherapy, similar to what has been seen in some of the upper GI cancers in the last couple of years. Now, before you started this paper or this work with Tempus, what was known about the landscape of biliary tract cancers and what have been the standard approaches of management for advanced biliary tract cancers? Dr. Yarchoan: You know, many of us who treat biliary tract cancers have joked for years that we treat the lung cancer of the GI cancer world because so many of these cancers have actionable molecular alterations. I think that's something that has been known for a long time. Over the last couple of years, for the first time, we have multiple drug approvals in cholangiocarcinoma for molecularly defined subsets of disease. So, for example, we have now inhibitors of FGFR2 that have been approved for FGFR2 fusions or rearrangements. We have an IDH1 inhibitor approved for cholangiocarcinoma. There are some tumor agnostic approvals like for BRAF and NTRK, all of which we do occasionally find in biliary tract cancer. So, you know I think it's been known for a long time that looking for molecular alterations is fruitful in cholangiocarcinoma. You often find these things and these cancers often respond to these agents. I think what is unique here is we've taken this knowledge and first of all, this is the largest series of biliary tract cancer that has ever been profiled to our knowledge, and other profiling efforts have been international. But we know that biliary tract cancer in Southeast Asia can sometimes be different from what we see here in the U.S. because there, those cancers are often caused by liver flukes, which we don't tend to see as much in the U.S. So, the genetics can be somewhat different. And finally, I think what is unique about our paper is that we have actually correlated these molecular differences, these molecular drivers of cholangiocarcinoma. And we've correlated these drivers with the RNA from the same tumor to really understand when you have a tumor that is for example, FGFR2 fusion or rearrangement, what is typically found in the immune microenvironment from that same tumor. Dr. Naqash: Thank you for that explanation. Now, going back to why biliary tract cancer's potentially not as responsive to immune checkpoint inhibitors as some of the other GI-based tumors — pancreatic cancer, as you very well know, has a certain tumor microenvironment associated with presence of fibroblasts and other immunosuppressive macrophages that result in lack of response to immunotherapy-based combinations. What is unique in biliary tract cancers, as you've nicely explained in the discussion or your introduction, that based on Keynote-158, the response rates have generally been in the range of 2 to 10%. So, what is unique here that results in tumors being not so responsive to immunotherapy-based combinations? Dr. Yarchoan: Yeah, biliary tract cancers tend to be fairly immune resistant cancers. As you mentioned, the response rate to single agent anti PD-1 immunotherapy is probably in a range of about 5 to 10% in most studies. We do have new data now from the TOPAZ-1 study, this is a randomized first line study of Gemcitabine Platinum with or without durvalumab, which is a PDL1 inhibitor where the addition of durvalumab did modestly improve survival. So, there is some activity for immunotherapy, but it's quite low as you mentioned. And again, I think that we're still learning why this is, but cholangiocarcinoma tends to have, number one, a very low tumor mutation burden. So, the total number of mutations, which is a surrogate for the number of neoantigens that the immune system can see tends to be low. But also, when we look at the immune microenvironment at these cancers, we tend to find relatively low numbers of effector T cells in the microenvironment, which are an anti-tumor subset. We tend to find high numbers of immunosuppressive cell types, M2 macrophages and T regulatory cells. And these tumors also tend to have a lot of stroma which can impede the immune system coming in. So, the two major accesses that can determine immune sensitivity, the mutational burden in the immune cells, and the microenvironment, both point to an immune suppressed tumor type. Dr. Naqash:  Totally agree. And I think that's why findings that you describe in this paper have a lot of relevance to precision medicine and how we can approach biliary tract cancers, not just anatomically but also from a molecular standpoint. Going back to lung cancer analogy, small cell lung cancer until a few years back was considered one entity and now, it is three to four different entities based on some transcriptional factors which determine how patients respond. And I believe there is something similar going on here like you described. So, now taking a deeper dive into the paper, you did mutational signature analysis clustering, and then you also assessed RNA. What would some of the mutation-specific findings associated with whether tumors were intrahepatic or extrahepatic gallbladder in this manuscript? Dr. Yarchoan: Sure. So, we, as you mentioned, did some cluster analysis looking at the driver mutations in cholangiocarcinoma. And what we found were essentially, there appeared to be four distinct subsets of these cancers. One subset which has been reported in other similar cluster analyses, including an international cluster analysis; one subset really appears to be driven by FGFR2 fusions or rearrangements and is entirely an intrahepatic cholangiocarcinoma subset. And we found that this subset tended to have the lowest immune infiltration of any of the four subsets that we looked at. A second subset, which we called mutational cluster three, was both intrahepatic and extrahepatic disease. And the most common mutation was really in CDKN2A or N2B. The second cluster that we looked at, clusters 1, 2, 3, 4 — I think is one of the most interesting clusters. And this is a cluster that was enriched for genes that seemed to alter the epigenome of the tumor. So, for example, IDH1 mutations, which we know result in an oncometabolite 2HG were common in the subset also ARID1A and PBRM1 were common. And then finally, the largest subset of all were the tumors that had frequent mutations in KRAS, TP53 among other mutations. We found that this was the most inflamed cluster, had the highest PD-L1 expression, slightly enriched in the extrahepatic subset versus intrahepatic subset. Dr. Naqash: Definitely interesting findings based on the cluster analysis and the mutations in each cluster. Going to cluster one where you have found that TP53, ATM, et cetera, mutations are commonly altered genes, are you suggesting based on some of this work that the immune inflamed tumor microenvironment could potentially be linked to TP53, which is cell cycle checkpoint, which when altered could result in higher DNA damage similarly with ATM being in the DNA damage pathway. Could that be a potential explanation for why these alterations are resulting in a hot tumor immune microenvironment? Dr. Yarchoan: Certainly, could be. You know, obviously, we can't prove that. This was correlative, but I think that would certainly explain what we found. Dr. Naqash: And again, going back to cluster four with FGFR2 and BAP1 alterations, which had the lowest PD-L1 and lowest immune microenvironment inflammatory signature, is that potentially a cluster that you think would most commonly benefit from targeted therapies rather than immune checkpoint-based therapies? Dr. Yarchoan: That's our hypothesis here. This was a subgroup that appeared to be non-inflamed, had a low mutational burden. Genomically, I would call this a stupid cancer in the sense that there's a very powerful driver mutation and not a whole lot else going on here. It seems like the sort of tumor that may benefit from targeted therapy. I think what we don't know, and one of the questions that immediately comes out of this work is, is FGFR2 itself immunosuppressive and that's why we don't find a lot of immune cells. And if so, it raises the question whether these sort of cluster four tumors would benefit from a combination approach of targeted therapy plus immunotherapy. And so, I think that's an open question, something that we hope to look into. Dr. Naqash: Definitely, leads to potential subsequent work in this field to expand more on these findings. Now, going back to some of the other important findings in your paper, you described actionable biomarkers in the biliary tract cancers based on proven trials with specific therapies. One of the questions that I had was you take TMB ≥10 as a potentially actionable biomarker. Is that true for biliary tract cancers? Because there's data from different groups showing that different TMB cutoffs have different meaning for different types of tumors. So, is 10 a cutoff where you are reasonably comfortable in saying that potentially, single agent immunotherapy may work and TMB here is predictive of outcomes, or do you think a higher TMB is probably more relevant in these cancers that are generally not immune responsive? Dr. Yarchoan: Yeah, the approval for pembrolizumab in high TMB tumors has been controversial. I think probably more controversial than it should be. But Keynote-158, which was sort of a prospectively analyzed study of pembrolizumab and multiple tumor histologies, actually included biliary tract cancers. And the response rate in that study for biliary tract cancer in the TMB high group again, small numbers of patients but, was consistent with pembrolizumab being very active. I have to say in my own clinic, I've had some absolutely spectacular responses for high TMB biliary tract cancer, and so I tend to believe the data. I've actually had complete responses. I've had patients downstage to surgery who went on single agent anti PD-1. So, I think this is an important group of patients and I think it is a group that we shouldn't miss for biliary tract cancer. Dr. Naqash: Definitely agree with you. All of us strive as medical oncologists to get some of those complete responses that don't come often very commonly or easily. But it's always nice to see those responses and individuals especially with these biomarker-specific tumors with high TMB or high PD-L1. Now, other findings from your paper, you describe mutual exclusivity of two mutations in a certain subgroup, which was TP53 and BAP1. Could you explain the clinical relevance or the molecular significance of these mutually exclusive mutations and what they might mean in the context of this tumor? Dr. Yarchoan:The short answer is these were clearly in different immune subsets and different molecular subsets. Again, the TP53 belonged to what we called cluster one. Usually, went with KRAS, was more common in extrahepatic disease. The BAP1 mutations tended to go along with FGFR2 fusions or rearrangements, was intrahepatic. But exactly why these were mutually exclusive, why was it not evolutionarily advantageous for tumors to have both of these things at once? You know, I think remains an unanswered question. There's certainly a hypothesis for why the tumor wouldn't need both, but I don't know. Dr. Naqash:  And you also looked at PD-L1 and tumor mutational burden across the biliary tract tumor subtypes. Could you tell us more about some of those findings? Dr. Yarchoan: Yeah, for sure. I mean, I think our cluster one, which again was the most inflamed cluster, had more KRAS, more TP53 — not surprisingly seemed to have the most immune infiltration, the highest PD-L1 expression in a trend towards a higher tumor mutation burden as well. Not totally surprising. I don't want to over-interpret that finding though because we've looked now at the prospective data from TOPAZ-1 where patients got GemCis with or without durvalumab. As a matter of fact, PD-L1 was not a very strong predictor for durvalumab benefit in that study. So, I wouldn't over-interpret the trend towards higher PD-L1 expression in that subset. It may not be very clinically actionable. Dr. Naqash:  Sure. Now, another finding is the TMB comparisons across the biliary tract cancer subtypes. And to me, it seemed like the TMB, median TMB, was slightly different but not significantly different that may not necessarily have a huge clinical relevance. Do you agree with that? What are your thoughts on that side? Dr. Yarchoan: We're in an era now where we just get TMB at an individual patient level. So, I don't think we're going to be relying on cluster analysis to figure out a patient's TMB. So, I don't think it's necessarily clinically actionable. I do think there were some findings here that are interesting from a research perspective. For example, ARID1A was associated with a higher tumor mutation burden; something that's been reported in other tumor types and that's certainly interesting and something that should be followed up on, I think, from a research standpoint. Dr. Naqash: Excellent. Now, last figure that I came across, which was again, very interesting, was that you analyze association between all the different mutations and different immune gene signatures. And it seemed based on the figure that TP53, again, stood out when you correlated with PD-L1 or CDA T cell or other immune inflammatory gene signatures. Is there something going on with TP53 here that you think is potentially relevant co-mutation in this tumor, which could lead to some novel therapeutic combination approaches? Dr. Yarchoan: Yeah, I don't want to over-interpret our work, but I agree, it's very interesting and this is a topic that is being investigated in many tumor types because TP53 is something that appears in many tumors including the ones that you treat. So, I think this is particularly relevant because we have a bunch of TP53 targeted therapies coming down the pike. How those will modulate the tumor immune microenvironment is an interesting topic. So, maybe just for sake of discussion, are you finding the same thing in lung cancer and what's the thought process in lung cancer now? Dr. Naqash:  Yes, again, very interesting question. So, we actually had some data last year that we presented in the context of lung cancer in STK11, which is again, commonly found in pancreatic and biliary cancers also. And we saw TP53 co-mutated tumors had a very high immune inflammatory gene signature with all the different aspects of immune infiltration or Interferon gamma upregulation (IFN-γ). So, likely, our assessment was that this was potentially linked to the cell cycle aspect and higher neoantigens for DNA damage. So, something common probably going on here in this tumor type as well as you mentioned. So, one of the other things that I came across, which is interesting and I've come across a patient actually a few years back with cholangiocarcinoma, but that was associated with a liver fluke. The tumors that you assess using the Tempus database obviously, were from North America and did not have Asian patients. And from my understanding, TOPAZ-1 did include a decent number of patients from Asia. So, have you looked at or is there a potential reason to believe that liver fluke-associated tumors may have a higher inflammatory signature or has there been any data in comparing liver fluke versus non-liver fluke-associated biliary tract tumors to see what could be the genomic transcriptomic differences there? Dr. Yarchoan: Yeah, as you mentioned, our study was purely for North American patients. It's not that there were no Asian patients. There certainly were Asian patients, including patients who may have been born in Southeast Asia but immigrated here. There have been other analyses of the molecular landscape of biliary tract cancer that were international and included more patients from Asia, including a paper in Cancer Discovery a couple of years ago that I think is worth reading. Overall, I think there is some data that this subgroup of patients may have a unique tumor immune microenvironment and unique mutational landscape. We tend to find more for two in these patients. They do tend to be, I think, a little more inflamed, have more PD-L1 expression. Interestingly, in the TOPAZ-1 study, which again, was the prospective study of durvalumab, there appeared to be more benefit to durvalumab in patients in Asia than patients in the West. And it does raise the question whether that could be mediated in part by this liver fluke ideology. So, again, certainly not a settled question, but something interesting that should be followed up on. Dr. Naqash:Definitely interesting. I would again like to thank you Dr. Yarchoan and your team for this excellent work and sharing all your thoughts with us today, and giving us more insights into biliary tract cancers. On behalf of JCO PO, I'd like to thank you for considering JCO PO as the final destination for this interesting work, and hopefully, you consider JCO PO for future work as well. Dr. Yarchoan: Well, thank you for highlighting our work and for the opportunity to publish, and thanks for this discussion. Dr. Naqash: Absolutely. It's been a pleasure talking to you today, and hopefully, our audience will find this conversation equally intriguing and interesting. Thank you for listening to JCO Precision Oncology Conversations. You can find all our shows, including this one at asco.org/podcasts or wherever you get your podcasts. To stay up to date, be sure to follow and share JCO PO content on Twitter. Our Twitter handle is @JCOPO_ASCO. All JCO PO articles and series can be found at ascopubs.org/journals/po.   Voiceover:  The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement.   Disclosures Mark Yarchoan  Consulting or Advisory Role: Eisai, Exelixis, AstraZeneca, Genentech/Roche, Replimune, Hepion Pharmaceuticals  Research Funding: Bristol Myers Squibb (Inst), Merck (Inst), Exelixis (Inst), Incyte (Inst)   Guest Bio Dr. Mark Yarchoan, MD, is a medical oncologist focused on hepatobiliary malignancies at the Johns Hopkins Hospital and co-director of Liver Multidisciplinary Clinic.

This week we welcomed long-time DMB collaborator Sam Erickson to the podcast! Sam was an integral part in documenting the band's early years as a photographer and videographer. We talk about everything from their 1996 European tour with Bob Dylan, his holy grail BTCS documentary, the incredible Dave & Tim Radio City DVD, the other musical beginnings and careers he helped document (John Mayer, P Diddy, My Morning Jacket, Trey Anastasio and more) and what's next for him. Big thanks to Sam for joining us - enjoy!

Featuring an interview with Professor Juan Valle, including the following topics: Immunotherapy for patients with biliary tract cancers (BTCs) (0:00) Etiology and presentation of and recent advances in the management of cholangiocarcinoma (4:18) Targeting FGFR alterations in cholangiocarcinoma and other BTCs (12:47) Spectrum and management of toxicities associated with FGFR inhibitors (19:33) Targeting driver mutations beyond FGFR (28:16) Case: A man in his early 60s with intrahepatic cholangiocarcinoma, an FGFR2 fusion and an IDH1 R132C mutation (35:53) Case: A woman in her early 60s with intrahepatic cholangiocarcinoma and an IDH1 mutation that did not respond to third-line ivosidenib (41:49) Case: A woman in her early 60s with gallbladder cancer who received first-line chemotherapy with pembrolizumab (46:15) CME information and select publications

Featuring a slide presentation and related discussion from Professor Juan Valle, including the following topics: Management of biliary tract cancers (BTCs) with targetable mutations (0:00) Management of BTCs without targetable mutations (13:59) Novel targets and treatments for cholangiocarcinoma and other BTCs (20:19) CME information and select publications

The finance police are coming for the digital asset industry -- but are they moving fast enough, or will the sector swiftly improve its compliance capabilities to get out ahead of the regulators? Where does this leave investors? Financial News' Trista Kelley, Jeremy Chan speak to Charles Allen, Chairman and CEO of BTCS, for the inside track. 

What if I told you that NFTs might become the future of voting? Listen in as I speak with Charles Allen, Chairman and CEO of BTCS, about cryptocurrencies, NFTs, blockchain and why we should care. Charles explains the different types and why one would invest in any of them. He will also take us through the various use cases. Finally, he addresses some of your questions and concerns around volatility. NOTE: Bitcoin and other cryptocurrencies are a very speculativeinvestment and involves a high degree of risk. Investors must have thefinancial ability, sophistication/experience and willingness to bear the risksof an investment, and a potential total loss of their investment.Note to All Readers: The information presented andopinions expressed are solely the views of the podcast host commentator andtheir guest speaker(s).  AllianceBernstein L.P. or its affiliates makes norepresentations or warranties concerning the accuracy of any data. There is noguarantee that any projection, forecast or opinion in this material will berealized. Past performance does not guarantee future results. The viewsexpressed here may change at any time after the date of this podcast. Thispodcast is for informational purposes only and does not constitute investmentadvice. AllianceBernstein L.P. does not provide tax, legal or accountingadvice. It does not take an investor's personal investment objectives orfinancial situation into account; investors should discuss their individualcircumstances with appropriate professionals before making any decisions. Thisinformation should not be construed as sales or marketing material or an offeror solicitation for the purchase or sale of any financial instrument, productor service sponsored by AllianceBernstein or its affiliates.The [A/B] logo is a registered service mark ofAllianceBernstein, and AllianceBernstein® is a registered service mark, used bypermission of the owner, AllianceBernstein L.P.

Narcelio, Otto e Ricardo vem para contar como solucionaram o enigma do livro "Satoshi", do Rafael Boskovic. Detalhes sobre o livro e o enigma: https://www.rafaelboskovic.com.br/satoshi MINUTAGEM 00:00 Sala de espera 03:20 Vídeo "Cheque os seus privilégios financeiros" 08:13 Introdução 09:42 Apresentação dos convidados Rafael Boskovic, Narcélio, Otto, Arab e Ricardo 11:00 O enigma de 200 BTCs ainda está valendo? 14:21 Diversos artistas criaram enigmas para divulgar o Bitcoin 16:08 O enigma do livro "Satoshi" 17:18 Por que Rafael criou o enigma e qual foi sua inspiração? 19:06 Como começou a ser criado o enigma do livro "Satoshi"? 19:44 Como os envolvidos começaram a procurar nomes e resolver o enigma 24:50 O filtro de referências e a formação da equipe para encontrar a seed 28:27 Referências geográficas e a quantidade de tempo usado para testar os nomes 38:00 Como funcionava o programa para achar a seed e o algoritmo da Warp Wallet 44:39 A referência sobre Bill Gates que não acreditaram ser verdadeira 45:35 A ferramenta que utilizaram para separar as informações do livro 47:25 "E se alguém criar uma carteira igual a minha?" 49:07 A descoberta do penúltimo nome e a inesperada ajuda de um perfil suspeito do Twitter 57:53 O pressentimento de Narcélio sobre o último nome e a sorte em acertá-lo 01:00:53 Existe diferenças entre o enigma do livro comparado com os de quadros? 01:04:57 Promoção inédita do livro "Satoshi", não perca! ________________ APOIE O CANAL https://bitcoinheiros.com/apoie/ ⚡ln@pay.bitcoinheiros.com Loja dos Bitcoinheiros https://loja.bitcoinheiros.com/ SIGA OS BITCOINHEIROS: Site: https://www.bitcoinheiros.com Youtube: https://www.youtube.com/bitcoinheiros Twitter: https://www.twitter.com/bitcoinheiros Allan - https://www.twitter.com/allanraicher Dov - https://twitter.com/bitdov Becas - https://twitter.com/bksbk6 Ivan - https://twitter.com/bitofsilence Instagram: https://www.instagram.com/bitcoinheiros Facebook: https://www.fb.com/bitcoinheiros Podcast: https://anchor.fm/bitcoinheiros APOIE O CANAL: - Dê uma gorjeta em Bitcoin: https://bitcoinheiros.com/apoie/ - Inscreva-se no canal - Deixe seu comentário no vídeo - Dê um like no vídeo - Compartilhe o vídeo e o canal com amigos e familiares na sua rede social - Envie um email com seu comentário e sugestões: bitcoinheiros@protonmail.com COMO GUARDAR SEUS BITCOINS? Bitcoinheiros recomendam o uso de carteiras Multisig com Hardware Wallets de diferentes fabricantes. Busque por "canivete bitcoinheiro" em nosso canal para saber mais. - COLDCARD - https://store.coinkite.com/promo/bitcoinheiros (use o código bitcoinheiros para ganhar 5% de desconto) - TREZOR E BITBOX02 PARA RESIDENTES NO BRASIL E AMÉRICA D --- Send in a voice message: https://anchor.fm/bitcoinheiros/message

Crypto Corner Podcast 749: Stocks discussed: (NasdaqCM: BTCS) (NasdaqCM: RIOT) (NasdaqCM: CLSK)